

# Linnea M Baudhuin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9206876/publications.pdf>

Version: 2024-02-01

44  
papers

1,646  
citations

516710

16  
h-index

315739

38  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2942  
citing authors

#	ARTICLE	IF	CITATIONS
1	Point of care CYP2C19 genotyping after percutaneous coronary intervention. <i>Pharmacogenomics Journal</i> , 2022, , .	2.0	0
2	Harmonizing the Collection of Clinical Data on Genetic Testing Requisition Forms to Enhance Variant Interpretation in Hypertrophic Cardiomyopathy (HCM). <i>Journal of Molecular Diagnostics</i> , 2021, 23, 589-598.	2.8	5
3	Genomics Integration Into Nephrology Practice. <i>Kidney Medicine</i> , 2021, 3, 785-798.	2.0	13
4	Hypertrophic Cardiomyopathy in the General Population. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1111-1113.	2.8	0
5	Predictive and Precision Medicine with Genomic Data. <i>Clinical Chemistry</i> , 2020, 66, 33-41.	3.2	7
6	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 761.	7.4	257
7	All Clinical Exomes Are Not Alike: Coverage Matters. <i>Clinical Chemistry</i> , 2020, 66, 9-11.	3.2	1
8	Molecular Diagnostics: Going from Strength to Strength. <i>Clinical Chemistry</i> , 2020, 66, 1-2.	3.2	2
9	Consumer-initiated Genetic Testing and Pharmacogenomics. <i>Advances in Molecular Pathology</i> , 2019, 2, 133-142.	0.4	1
10	Variability in gene-based knowledge impacts variant classification: an analysis of FBN1 missense variants in ClinVar. <i>European Journal of Human Genetics</i> , 2019, 27, 1550-1560.	2.8	12
11	Clopidogrel Pharmacogenetics. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007811.	3.9	139
12	International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. <i>Pharmacogenetics and Genomics</i> , 2019, 29, 76-83.	1.5	13
13	Genetic variation in statin intolerance and a possible protective role for <i>UGT1A1</i> . <i>Pharmacogenomics</i> , 2018, 19, 83-94.	1.3	10
14	Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals. <i>European Journal of Human Genetics</i> , 2017, 25, 410-415.	2.8	10
15	Miniaturized Nanopore DNA Sequencing: Accelerating the Path to Precision Medicine. <i>Clinical Chemistry</i> , 2017, 63, 632-634.	3.2	7
16	Clinical UGT1A1 Genetic Analysis in Pediatric Patients: Experience of a Reference Laboratory. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 327-335.	3.8	8
17	Technical Advances for the Clinical Genomic Evaluation of Sudden Cardiac Death. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	21
18	Direct-to-Consumer Genetic Testing in the Personalized Medicine Era. <i>Point of Care</i> , 2017, 16, 120-123.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Classifying Germline Sequence Variants in the Era of Next-Generation Sequencing. <i>Clinical Chemistry</i> , 2016, 62, 799-806.	3.2	0
20	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic. <i>Mayo Clinic Proceedings</i> , 2016, 91, 297-307.	3.0	83
21	Preemptive Pharmacogenomic Testing for Precision Medicine. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 438-445.	2.8	171
22	Decreased frequency of FBN1 missense variants in Ghent criteria-positive Marfan syndrome and characterization of novel FBN1 variants. <i>Journal of Human Genetics</i> , 2015, 60, 241-252.	2.3	18
23	“Big Data” in Laboratory Medicine. <i>Clinical Chemistry</i> , 2015, 61, 1433-1440.	3.2	29
24	Confirming Variants in Next-Generation Sequencing Panel Testing by Sanger Sequencing. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 456-461.	2.8	109
25	Increased frequency of FBN1 truncating and splicing variants in Marfan syndrome patients with aortic events. <i>Genetics in Medicine</i> , 2015, 17, 177-187.	2.4	71
26	Genetic considerations in the treatment of familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2015, 10, 387-403.	0.4	2
27	What Is the True Prevalence of Hypertrophic Cardiomyopathy?. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1845-1846.	2.8	14
28	Abstract 11043: Lipoprotein(a) Cholesterol but not Lipoprotein (a) Mass is Significantly Correlated With Angiographic Coronary Artery Disease and Major Adverse Events. <i>Circulation</i> , 2015, 132, .	1.6	1
29	The FDA and 23andMe: Violating the First Amendment or Protecting the Rights of Consumers?. <i>Clinical Chemistry</i> , 2014, 60, 835-837.	3.2	14
30	Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time” Using Genomic Data to Individualize Treatment Protocol. <i>Mayo Clinic Proceedings</i> , 2014, 89, 25-33.	3.0	250
31	Genetic and biochemical analyses in dyslipidemic patients undergoing LDL apheresis. <i>Journal of Clinical Apheresis</i> , 2014, 29, 256-265.	1.3	4
32	UGT1A1 Genetic Analysis as a Diagnostic Aid for Individuals with Unconjugated Hyperbilirubinemia. <i>Journal of Pediatrics</i> , 2013, 162, 1146-1152.e2.	1.8	44
33	How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 25-37.	3.1	15
34	Determining the Optimal Approach for Government-Regulated Genetic Testing. <i>Clinical Chemistry</i> , 2011, 57, 7-8.	3.2	3
35	Relation of ADRB1, CYP2D6, and UGT1A1 Polymorphisms With Dose of, and Response to, Carvedilol or Metoprolol Therapy in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2010, 106, 402-408.	1.6	51
36	Prevalence and Spectrum of Large Deletions or Duplications in the Major Long QT Syndrome-Susceptibility Genes and Implications for Long QT Syndrome Genetic Testing. <i>American Journal of Cardiology</i> , 2010, 106, 1124-1128.	1.6	51

#	ARTICLE	IF	CITATIONS
37	Genetics of coronary artery disease: focus on genome-wide association studies. American Journal of Translational Research (discontinued), 2009, 1, 221-34.	0.0	14
38	Warfarin pharmacogenetics: ready for clinical utility?. Clinical Laboratory Science: Journal of the American Society for Medical Technology, 2009, 22, 151-5.	0.1	0
39	Genetic markers for coronary artery disease. Clinical Laboratory Science: Journal of the American Society for Medical Technology, 2009, 22, 226-32.	0.1	0
40	Comparison of three methods for genotyping the UGT1A1 (TA) <sub>n</sub> repeat polymorphism. Clinical Biochemistry, 2007, 40, 710-717.	1.9	25
41	MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. Journal of Cancer Research and Clinical Oncology, 2006, 132, 159-162.	2.5	14
42	Use of Microsatellite Instability and Immunohistochemistry Testing for the Identification of Individuals at Risk for Lynch Syndrome. Familial Cancer, 2005, 4, 255-265.	1.9	109
43	Analysis of hMLH1 and hMSH2 Gene Dosage Alterations in Hereditary Nonpolyposis Colorectal Cancer Patients by Novel Methods. Journal of Molecular Diagnostics, 2005, 7, 226-235.	2.8	28
44	Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein(a) method. Clinical Biochemistry, 2004, 37, 481-488.	1.9	20